New Equilibrium Biosciences

What New Equilibrium Biosciences does

New Equilibrium Biosciences is a Cambridge, Massachusetts-based for-profit biotechnology company founded in 2019 that builds an AI platform to learn biophysics and surface opportunities for structure-based molecular design. The platform is positioned at the intersection of machine learning and computational biophysics, targeting structure-based drug design — a workflow where the three-dimensional conformations of biological targets inform compound selection. The company operates with a small team of 1–10 employees and was co-founded by Virginia Burger (CEO and President) and Peter Tompa.

The company has raised approximately $10.5 million in disclosed funding across four events between October 2019 and March 2021, anchored by a $10 million round in March 2021 led by RA Capital Management with participation from Petri. Earlier capital included a $250,000 round from Petri (October 2019), a National Science Foundation grant of $255,872 (September 2020), and a Massachusetts Life Sciences Center program award (May 2020). Investor quality is high for the stage — RA Capital Management is a specialist biotech investor — but no customer logos, partnerships, revenue model, pricing, or product launch details are disclosed in the available source material.

The revenue model, customer segments, and go-to-market motion are not disclosed. Given the company's stage, small headcount, and the typical monetization paths for AI-driven drug discovery platforms (software licensing, target-discovery collaborations, or co-development agreements with pharma), the company is most likely in a pre-commercial or early-pilot stage. The publicly listed website (newequilibriumbio.com) currently displays unrelated third-party Turkish-language content about a betting platform, which indicates the domain is no longer under active company control — a material data-integrity and continuity concern for any prospective diligence.

Name

New Equilibrium Biosciences

Legal name

New Equilibrium Biosciences

Website

https://newequilibriumbio.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

New Equilibrium Biosciences is a Cambridge, MA-based AI platform company founded in 2019 that applies machine learning to biophysics to enable structure-based drug design, serving the computational drug discovery market.

Ownership category

akta.pro rank

Product category

Computational Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Computational drug discovery
• Structure-based design
• Biophysics machine learning
• Protein structure prediction
• AI drug design platform

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

New Equilibrium Biosciences provides an AI-driven platform that learns biophysics to reveal opportunities for structure-based molecular design. The platform enables researchers to model protein structures and biophysical interactions, supporting rational design of therapeutics and other biomolecules. It targets biopharma and academic users engaged in computational drug discovery and protein engineering.

Product overview

No product information available for New Equilibrium Biosciences in the provided source data. The source material contains content about Cratosroyalbet (a betting platform) rather than biotechnology products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Biophysics AI Platform

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Ginkgo Bioworks: Public synthetic biology / cell-engineering platform; less direct on protein design but comparable as a Cambridge-based AI-bio infrastructure company pursuing engineering biology.
• Isomorphic Labs: Alphabet-owned drug discovery company building an AI-driven computational platform rooted in DeepMind's AlphaFold biology work; competes in the AI-for-structure-based-drug-design category at vastly greater scale.
• Schrödinger, Inc. Public computational chemistry/drug-discovery platform with physics-based molecular modeling and ML — overlaps with New Equilibrium's biophysics-meets-AI approach for structure-based design.
• AbCellera Biologics: Public antibody discovery platform that combines high-throughput screening with ML; broader and more established but overlaps in AI-augmented biologics discovery.
• Recursion Pharmaceuticals: Public AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML models; broader platform but directly comparable AI-for-bio thesis.

Emerging players

• Adaptyv Bio: AI protein engineering platform that integrates generative ML design with high-throughput wet-lab validation; closely comparable in offering an AI-driven protein-design service for biologics R&D.
• Menten AI: Early-stage AI protein design company building generative models for novel enzymes and therapeutic proteins; directly comparable technology and stage.
• Insitro: ML-driven drug discovery platform combining high-throughput biology with AI models; adjacent peer in the AI-for-biologics space targeting pharma partnerships.

Direct peers

• Generate Biomedicines: Flagship-backed AI platform for generative biology and de novo protein/antibody design; competes head-on with New Equilibrium's AI-learned-biophysics-for-structure-based-design thesis.
• Cradle Bio: AI/ML platform for protein engineering and design, serving biologics R&D teams; directly comparable in offering AI tooling to enable structure-based protein optimization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/NEQBio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Equilibrium Biosciences